Jack Ball - 14 Nov 2022 Form 4 Insider Report for Cytek Biosciences, Inc. (CTKB)

Role
Director
Signature
/s/ Valerie Barnett, Attorney-in-Fact for Jack Ball
Issuer symbol
CTKB
Transactions as of
14 Nov 2022
Net transactions value
-$228,640
Form type
4
Filing time
16 Nov 2022, 16:53:51 UTC
Previous filing
03 Jun 2022
Next filing
30 Nov 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTKB Common Stock Options Exercise $6,400 +16,000 +533% $0.4000* 19,000 14 Nov 2022 Direct
transaction CTKB Common Stock Sale $235,040 -16,000 -84% $14.69 3,000 14 Nov 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTKB Stock Option (Right to Buy) Options Exercise $0 -16,000 -60% $0.000000 10,666 14 Nov 2022 Common Stock 16,000 $0.4000 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2022.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.53 to $14.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.